T1	Participants 422 475	phase IIb single-center randomized, controlled trial.
T2	Participants 870 899	Sixty patients were recruited
T3	Participants 1551 1573	G-CSF-treated patients
T4	Participants 1884 1913	patients with ischemic stroke
